- Home
- JSPR vs ALXO Comparison
JSPR vs ALXO Comparison
Compare JSPR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ALXO
- Stock Information
- Founded
- JSPR 2018
- ALXO 2015
- Country
- JSPR United States
- ALXO United States
- Employees
- JSPR N/A
- ALXO N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ALXO Health Care
- Exchange
- JSPR Nasdaq
- ALXO Nasdaq
- Market Cap
- JSPR 85.8M
- ALXO 28.3M
- IPO Year
- JSPR N/A
- ALXO 2020
- Fundamental
- Price
- JSPR $4.43
- ALXO $0.46
- Analyst Decision
- JSPR Strong Buy
- ALXO Strong Buy
- Analyst Count
- JSPR 10
- ALXO 6
- Target Price
- JSPR $62.50
- ALXO $4.14
- AVG Volume (30 Days)
- JSPR 155.4K
- ALXO 522.3K
- Earning Date
- JSPR 05-20-2025
- ALXO 05-08-2025
- Dividend Yield
- JSPR N/A
- ALXO N/A
- EPS Growth
- JSPR N/A
- ALXO N/A
- EPS
- JSPR N/A
- ALXO N/A
- Revenue
- JSPR N/A
- ALXO N/A
- Revenue This Year
- JSPR N/A
- ALXO N/A
- Revenue Next Year
- JSPR N/A
- ALXO N/A
- P/E Ratio
- JSPR N/A
- ALXO N/A
- Revenue Growth
- JSPR N/A
- ALXO N/A
- 52 Week Low
- JSPR $3.13
- ALXO $0.44
- 52 Week High
- JSPR $26.84
- ALXO $17.50
- Technical
- Relative Strength Index (RSI)
- JSPR 44.42
- ALXO 34.36
- Support Level
- JSPR $4.27
- ALXO $0.49
- Resistance Level
- JSPR $5.67
- ALXO $0.55
- Average True Range (ATR)
- JSPR 0.44
- ALXO 0.05
- MACD
- JSPR 0.01
- ALXO 0.01
- Stochastic Oscillator
- JSPR 28.32
- ALXO 8.77
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.